November 27, 2013
Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of Mesoblast (MSB: ASX), an
Australian-headquartered biotechnology company focused on adult stem therapies.
Mesoblast's pipeline is based on its proprietary mesenchymal precursor cell (MPC) and culture-expanded mesenchymal stem cell (MSC) technologies. Edison's report,
Precursor to success
, discusses Mesoblast's two technology platforms (MPCs and MSCs) that have to date generated nine clinical candidates (four in Phase III, five in Phase II). The report goes on to analyse the three strategic partnerships with Teva, JCR and Lonza, which underpin the key late-stage programmes including Revascor that could provide
potential peak sales.
Edison's healthcare team value Mesoblast at
/share) based on a risk-adjusted net present value (rNPV) analysis, which could rise to
/share) if upcoming catalysts are positive.
For the full report see:
About Edison Investment Research
The launch of coverage on Mesoblast is part of a programme of research initiations on biotechnology companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in
. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in
. All reports Edison publishes are available to download free of charge from its website
Edison is authorised and regulated by the Financial Services Authority (
). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.